Printing And Publishing Tenders

KuwaitTenders provides latest updates on tenders from Printing And Publishing. The information is collected from various sources like: Purchaser's websites, News papers and other Kuwait Government Tenders sites.Subscriber can view and download unlimited number of public tenders, published by various agencies of Kuwait Government in Printing And Publishing Sector.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Etanercept (L04ab01) as Part of a So-Called Open House Model.
Conclusion of non-exclusive discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient etanercept (L04AB01) within the period from April 1st, 2024 to March 31st, 2026 with the possibility of concluding the contract at any time (open-house model ). They are in the open house processMedicines according to the BfArM list according to Section 35 Paragraph 5a SGB V (children's medicines) excluded.
Conclusion of non-exclusive discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicines with the active ingredient Etanercept (L04AB01) within the framework of a so-called open house model.
The AOK Rheinland-Pfalz/Saarland - The health insurance company offers discount contracts with the active ingredient etanercept (L04AB01) to all interested pharmaceutical companies without a selection decision. The contracts are concluded as part of an "open house model". The contracts offered are not exclusive; VeThe AOK Rheinland-Pfalz/Saarland - The Health Insurance Fund wishes to have income from all market participants (pharmaceutical companies). In the open house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform individualNegotiations will not be conducted.
The contract terms are a maximum of 24 months, the earliest contract start date is April 1st, 2024. All contracts end no later than 24 months after the earliest day of contract start, regardless of the date of conclusion of the respective contract. An accession or a Ve...

KWT Ref No.:  97302535

Deadline:  31 Jan 2026

(2024-DPS-1) modular transformer dynamic purchase system

KWT Ref No.:  97301953

Deadline:  19 Feb 2029

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Botulinum Toxin Type a (M03ax21) as Part of a So-Called Open House Model.
Conclusion of non-exclusive discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products with the active ingredient botulinum toxin type A (M03AX21) within the period from April 1st, 2024 to March 31st, 2026 with the possibility of concluding the contract at any time (open-house -Model). In the open house authorMedicines according to the BfArM list according to § 35 para. 5a SGB V (children's medicines) are excluded.
Conclusion of non-exclusive discount contracts in accordance with §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient botulinum toxin type A (M03AX21 ) as part of a so-called Open House Modells.
The AOK Rhineland-Palatinate/Saarland - The health insurance company offers discount contracts with the active ingredient botulinum toxin type A (M03AX2) to all interested pharmaceutical companies without a selection decision. The contracts are concluded as part of an "open house model". The versions offeredsluggish are not exclusive; Contracts with all market participants (pharmaceutical companies) are desired by AOK Rheinland-Pfalz/Saarland - The Health Insurance Fund. In the open house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures can be found herend uniform - individual negotiations are not conducted.
The contract terms are a maximum of 24 months, the earliest contract start is April 1st, 2024. All contracts end no later than 24 months after the earliest day of contract start, regardless of the date of conclusion of the respective contract...

KWT Ref No.:  97294033

Deadline:  31 Jan 2026

Yleisradio Oy establishes a dynamic procurement system (hereinafter DPS) for the procurement of studio, transmission and broadcast technology products and services. The products and services covered by the procurement system, detailed in more detail, are:
1. Studio, transfer and broadcast technology intended for professional usesuch as video servers, encoders, sound desks, video matrices, prompters, virtualized production solutions, software-based media and media management solutions, IP-based technology and other similar technology. The products also include software related to the aforementioned, etca licenses.
2. Services related to studio, transmission and broadcast technology, such as integrator, installation, expert and commissioning services, equipment-related support and maintenance services and other similar services in connection with the products or purchased separately.
Procurable products and servicesut is defined in more detail in each DPS internal competition. A more detailed description of DPS and its operation is given in Appendix 1 of the request for participation.
Yle accepts all candidates who have submitted an application for participation and who meet the suitability requirements for candidates.
Stustudio, transmission and broadcast technology products and services DPS
Yleisradio Oy establishes a dynamic procurement system (hereinafter DPS) for the procurement of studio, transmission and broadcast technology products and services. The products and services covered by the procurement system, detailed in more detail, are:
1. Professions...

KWT Ref No.:  97293234

Deadline:  31 Dec 2027

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Adalimumab (L04ab04) as Part of a So-Called Open House Model.
Conclusion of non-exclusive discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient adalimumab (L04AB04) within the period from April 1st, 2024 to March 31st, 2026 with the possibility of concluding a contract at any time (open-house model ).
In the open house processMedicines according to the BfArM list according to § 35 Para. 5a SGB V (children's medicines) excluded.
Conclusion of non-exclusive discount contracts according to §§ 130a Para. 8/130c Para. 1 SGB V for medicines with the active ingredient adalimumab (L04AB04) within the period from April 1st, 2024 to March 31st, 2026 mWith the possibility of concluding a contract at any time. In the open house procedure, medicines according to the BfArM list according to Section 35 Para. 5a SGB V (children's medicines) are excluded.
The AOK Rhineland-Palatinate/Saarland - The health insurance company offers all interested pharmaceutical companies or the likewithout a selection decision, discount contracts with the active ingredient adalimumab (L04AB04). The contracts are concluded as part of an "open house model". The contracts offered are not exclusive; Contracts with all market participants (pharmaceutical companies) are signed by AOK Rheinland-Pfalz/Saarland - The health insurance company wanted. In the open house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform - individual negotiations are not carried out.
The contract terms are a maximum of 24 months, the earliest being V...

KWT Ref No.:  97291826

Deadline:  31 Jan 2026

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Infliximab (L04ab02) as Part of a So-Called Open House Model.
Conclusion of non-exclusive discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for drugs with the active ingredient infliximab (L04AB02) within the period from April 1st, 2024 to March 31st, 2026 with the possibility of concluding the contract at any time (open-house model ). They are in the open house processMedicines according to the BfArM list according to Section 35 Paragraph 5a SGB V (children's medicines) excluded.
Conclusion of non-exclusive discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicines with the active ingredient infliximab (L04AB02) within the framework of a so-called open house model.
The AOK Rheinland-Pfalz/Saarland - The health insurance company offers discount contracts with the active ingredient infliximab (L04AB02) to all interested pharmaceutical companies without a selection decision. The contracts are concluded as part of an "open house model". The contracts offered are not exclusive; VeThe AOK Rheinland-Pfalz/Saarland - The Health Insurance Fund wishes to have income from all market participants (pharmaceutical companies). In the open house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform individualNegotiations will not be conducted.
The contract terms are a maximum of 24 months, the earliest contract start date is April 1st, 2024. All contracts end no later than 24 months after the earliest day of contract start, regardless of the date of conclusion of the respective contract. An accession or a Ve...

KWT Ref No.:  97260942

Deadline:  31 Jan 2026

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Rivaroxaban (B01af01), only Film-Coated Tablets Excl. Potency 2.5Mg as Part of a So-Called...
Conclusion of non-exclusive discount agreements in accordance with Sections 130a Paragraph 8/130c Paragraph 1 SGB V for medicines with the active ingredient Rivaroxaban (B01AF01), only film-coated tablets excl. potency 2.5 mg as part of a so-called open house model.
Non-exclusive conclusion Discount contracts in accordance with Sections 130a Paragraph 8/130c Paragraph.1 SGB V on medicines with the active ingredient rivaroxaban (B01AF01), only film-coated tablets excluding potency 2.5 mg within the period from April 1, 2024 to March 31, 2026 with the possibility of concluding a contract at any time (open-house model). In the open house procedure, medicines are available in accordance with theBfArM list according to § 35 para. 5a SGB V (children's medicines) excluded.
Conclusion of non-exclusive discount contracts in accordance with §§ 130a para. 8/130c para. 1 SGB V for drugs with the active ingredient rivaroxaban (B01AF01), only film-coated tablets excluding potency 2.5mg as part of a so-called open house model.
The AOK Rhineland-Palatinate/Saarland - The health insurance company offers discount contracts with the active ingredient Rivaroxaban (B01AF01), only film-coated tablets excl. potency 2.5 mg, to all interested pharmaceutical companies without a selection decision. The contracts are concluded as part of an "Open House Modells". The contracts offered are not exclusive; Contracts with all market participants (pharmaceutical companies) are desired by AOK Rheinland-Pfalz/Saarland - The Health Insurance Fund. In the open house model, uniform conditions apply to all participants. Contract contents, con...

KWT Ref No.:  97256715

Deadline:  31 Jan 2026

  Chat with us